Priority Review For Zaltrap
Recently, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and partner Sanofi (NYSE:SNY) announced that their oncology candidate Zaltrap (aflibercept) will be reviewed on a priority basis by the US Food and Drug Administration (FDA). A decision from the US regulatory body is expected in the third quarter of 2012 (target date: August 4, 2012). We note that the [...]
Recently, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and partner Sanofi (NYSE:SNY) announced that their oncology candidate Zaltrap (aflibercept) will be reviewed on a priority basis by the US Food and Drug Administration (FDA). A decision from the US regulatory body is expected in the third quarter of 2012 (target date: August 4, 2012).
We note that the US regulatory authority generally reviews those drugs on a priority basis, which offer major advances in treating diseases that do not have adequate … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards